Quantcast
Last updated on April 18, 2014 at 6:03 EDT

Latest Sirtex Medical Limited Stories

2014-03-24 08:28:31

PRINCETON, N.J., March 24, 2014 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*....

2012-12-11 04:21:35

SYDNEY, December 11, 2012 /PRNewswire/ -- http://www.sirtex.com informs doctors, patients and investors about the world's most widely used and widely studied form of SIRT for all cancers in the liver Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors, nurses, patients and investors interested in learning more about SIR-Spheres microspheres, a form of radiotherapy targeting liver tumours that is gaining...

2012-02-03 01:00:00

PARIS, February 3, 2012 /PRNewswire/ -- 'SARAH' - a French national collaborative randomized controlled trial of radioembolization with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma is now open for recruitment The start of SARAH, a new randomized controlled trial to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (SIR-Spheres(R) microspheres; Sirtex Medical...